HELLO CHINA

INDUSTRY CLUSTER · Biomedicine

Xianyang Qindu pharmaceutical manufacturing

Qindu pharmaceutical firms mainly produce established dosage forms for regional markets. Similar product names do not imply the same formula, dosage form or approval holder; checks should match approval number, manufacturing licence, test specification, batch record and marketing-authorisation holder item by item.

Formation and regional foundations

Xianyang built dosage-manufacturing capacity around established medicine firms and high-tech parks. Regulators continually update company status through production inspections, sampling and licence disclosure, while listed-company reports add product mix, research spending and relations among manufacturing entities.

Qindu manufacturers cover traditional Chinese medicines, chemical preparations and related production. Product and supply review connects approval number, holder, site, formula or process, methods, package revision and distribution lot.

Core geography: Centred on traditional Chinese medicines, chemical preparations and pharmaceutical-packaging firms in Qindu’s production parks and Xianyang High-tech Zone, the boundary covers input testing, extraction and formulation, dosage production, quality release and distribution traceability. Entities are checked against regulatory inspections and published reports.

Qindu pharmaceutical manufacturing order path

Six nodes for understanding traditional Chinese medicines, chemical preparations and pharmaceutical-production services

Approval, material lot, production lot, test report, package revision and distribution destination remain linked. A distribution arrow does not transfer formula, licence or quality responsibility.

  • Approval information and formula — Qindu pharmaceutical manufacturing records the responsible party, input revision and release condition at “Approval information and formula”.
  • Incoming-material testing — Qindu pharmaceutical manufacturing records the responsible party, input revision and release condition at “Incoming-material testing”.
  • Extraction, compounding or granulation — Qindu pharmaceutical manufacturing records the responsible party, input revision and release condition at “Extraction, compounding or granulation”.
  • Dosage and packaging production — Qindu pharmaceutical manufacturing records the responsible party, input revision and release condition at “Dosage and packaging production”.
  • Quality testing and release — Qindu pharmaceutical manufacturing records the responsible party, input revision and release condition at “Quality testing and release”.
  • Distribution traceability and feedback — Qindu pharmaceutical manufacturing records the responsible party, input revision and release condition at “Distribution traceability and feedback”.

01 · Qindu pharmaceutical manufacturing: Define the buying question first

Chapter 1 takes its checks from Approval information and formula.

A pharmaceutical engagement starts with approval number, dosage form, strength, formula scope, holder and manufacturing site. One company name cannot lend another product or site its licence.

In decision 1, when Qindu pharmaceutical manufacturing moves from “Approval information and formula” to “Incoming-material testing”, version, lot and change records are easiest to lose. Decision 1 links inputs, process parameters and release results to show whether approval numbers, batch records, test results and distribution traceability are genuinely controlled.

Approval status is confirmed in original medicine-regulator records, including supplements or site changes. Group profiles and recruitment material describe organisation only.

02 · Qindu pharmaceutical manufacturing: Inputs and starting conditions

Chapter 2 takes its checks from Incoming-material testing.

API, herbs, excipients and packaging enter with supplier qualification, lot, test status and storage. Herbs also need botanical identity and origin rather than a trade name alone.

In decision 2, when Qindu pharmaceutical manufacturing moves from “Incoming-material testing” to “Extraction, compounding or granulation”, version, lot and change records are easiest to lose. Decision 2 links inputs, process parameters and release results to show whether approval numbers, batch records, test results and distribution traceability are genuinely controlled.

Receiving sampling prevents confusion among lots or containers and records retest and opened-container periods. A passed supplier audit does not exempt each delivery from testing.

03 · Qindu pharmaceutical manufacturing: How the core process connects

Chapter 3 takes its checks from Extraction, compounding or granulation.

Extraction, compounding or granulation records charge, temperature, time, solvent, endpoint and yield and explains deviations. Theoretical yield does not replace material balance or hide rework.

In decision 3, when Qindu pharmaceutical manufacturing moves from “Extraction, compounding or granulation” to “Dosage and packaging production”, version, lot and change records are easiest to lose. Decision 3 links inputs, process parameters and release results to show whether approval numbers, batch records, test results and distribution traceability are genuinely controlled.

Traditional-medicine extraction addresses botanical mix-up, solvent residue and concentration endpoint; chemical preparations may focus on API form and compatibility. The two do not share one process conclusion.

04 · Qindu pharmaceutical manufacturing: Where quality evidence sits

Chapter 4 takes its checks from Dosage and packaging production.

Tableting, filling, coating or liquid fill and packaging require in-process control, line clearance, equipment state and material identity. Uniform appearance does not establish assay, dissolution or seal.

In decision 4, when Qindu pharmaceutical manufacturing moves from “Dosage and packaging production” to “Quality testing and release”, version, lot and change records are easiest to lose. Decision 4 links inputs, process parameters and release results to show whether approval numbers, batch records, test results and distribution traceability are genuinely controlled.

Print, leaflet and regulated codes are checked against approvals, with obsolete components segregated and destroyed. Packaging error can block lawful release of conforming contents.

05 · Qindu pharmaceutical manufacturing: How to compare suppliers

Chapter 5 takes its checks from Quality testing and release.

Laboratory release uses the applicable method, reference standard, instrument state and sample custody and addresses out-of-specification or adverse trends. One certificate cannot show completed investigation.

In decision 5, when Qindu pharmaceutical manufacturing moves from “Quality testing and release” to “Distribution traceability and feedback”, version, lot and change records are easiest to lose. Decision 5 links inputs, process parameters and release results to show whether approval numbers, batch records, test results and distribution traceability are genuinely controlled.

Stability, retention and market samples resolve to the same lot and have storage and retest rules. A method transferred to another laboratory needs an applicability assessment.

06 · Qindu pharmaceutical manufacturing: Geography and delivery radius

Chapter 6 takes its checks from Distribution traceability and feedback.

Distribution traceability connects production lot, pack revision, consignee, transit condition and return status. Ambient medicines can also suffer heat or moisture and need environmental control.

In decision 6, when Qindu pharmaceutical manufacturing moves from “Distribution traceability and feedback” to “Approval information and formula”, version, lot and change records are easiest to lose. Decision 6 links inputs, process parameters and release results to show whether approval numbers, batch records, test results and distribution traceability are genuinely controlled.

Complaint investigation records event, sample condition, destination and same-lot trends and separates transit, use and manufacture. Returns cannot re-enter saleable stock without assessment.

07 · Qindu pharmaceutical manufacturing: Resource efficiency and compliance

Chapter 7 takes its checks from Approval information and formula.

Resource and compliance review separates medicine quality, worker health, emissions, hazardous waste and fire duties. Medicine-inspection date and scope remain visible and do not become permanent compliance.

In decision 7, when Qindu pharmaceutical manufacturing moves from “Approval information and formula” to “Incoming-material testing”, version, lot and change records are easiest to lose. Decision 7 links inputs, process parameters and release results to show whether approval numbers, batch records, test results and distribution traceability are genuinely controlled.

Inspection findings need owner, deadline, verification and closure evidence; an older result cannot cover a later line. Environmental or fire procedures also cover only named facilities.

08 · Qindu pharmaceutical manufacturing: Turn diligence into a decision

Chapter 8 takes its checks from Incoming-material testing.

The final decision collects licences, product list, quality agreement, batch-record sample, methods, stability and recall contacts. A representative lot also rehearses deviation, change and complaint investigation.

In decision 8, when Qindu pharmaceutical manufacturing moves from “Incoming-material testing” to “Extraction, compounding or granulation”, version, lot and change records are easiest to lose. Decision 8 links inputs, process parameters and release results to show whether approval numbers, batch records, test results and distribution traceability are genuinely controlled.

The contract sets notification timing for major deviation, recall, inspection and supply interruption and retains audit and exit rights. Price cannot replace continuing quality-information exchange.

Sources and reading notes

Annual reports, medicine inspections and regulatory updates separately support entity activity, inspection dates and regulatory matters. Product approvals, lines and group resources retain their subjects; a passed inspection is not projected to every lot, product or future period.

  • Published material confirms the boundary and main carrying spaces of Qindu pharmaceutical manufacturing, but district-wide totals cannot be assigned to one company.
  • Traditional Chinese medicines and chemical preparations use different inputs, processes and tests; approved-product count does not convert into deliverable capacity.
  • Marketing holder, contract manufacturer, packaging site and seller may differ. Company responsibility is confirmed for the product and current licence.

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

  • Shaanxi Dongtai Pharmaceutical Co Ltd — Shaanxi Dongtai Pharmaceutical Co Ltd contributes Production of traditional Chinese medicine preparations and common medicines within Qindu pharmaceutical manufacturing. Public sources establish the entity and product direction for Shaanxi Dongtai Pharmaceutical Co Ltd, while specifications, capacity, price and lead time remain order-specific.
  • Shaanxi Kanghui Pharmaceutical Co Ltd — Shaanxi Kanghui Pharmaceutical Co Ltd contributes Research, production and quality management for traditional Chinese medicine preparations within Qindu pharmaceutical manufacturing. Public sources establish the entity and product direction for Shaanxi Kanghui Pharmaceutical Co Ltd, while specifications, capacity, price and lead time remain order-specific.
  • Shaanxi Sun Simiao Gaoxin Pharmaceutical Co Ltd — Shaanxi Sun Simiao Gaoxin Pharmaceutical Co Ltd contributes Pharmaceutical preparations, production operations and quality release within Qindu pharmaceutical manufacturing. Public sources establish the entity and product direction for Shaanxi Sun Simiao Gaoxin Pharmaceutical Co Ltd, while specifications, capacity, price and lead time remain order-specific.
  • Request a company-record correction or removal — Requests are reviewed by a person, handled promptly after verification, free of charge and not tied to commercial cooperation.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.